FRM
ZVRA icon

Fox Run Management’s Zevra Therapeutics ZVRA Stock Holding History

Fox Run Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,884
Closed -$95.6K – 1351
2026
Q1 		$95.6K Sell
10,884
-13,838
-56% -$125K 0.02% 840
2025
Q4 		$222K Sell
24,722
-6,299
-20% -$59.6K 0.03% 776
2025
Q3 		$295K Buy
31,021
+19,770
+176% +$198K 0.05% 689
2025
Q2 		$99.1K Buy
+11,251
New +$91.3K 0.02% 805

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fox Run Management's ZVRA Position: Q2 2026 in Review

Fox Run Management sold out of Zevra Therapeutics (ZVRA) in Q2 2026, closing a stake of 10,884 shares — an estimated $95.6K sold.

Fox Run Management first reported a position in ZVRA in Q2 2025 and held it in 4 quarters. The position peaked at $295K in Q3 2025. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Fox Run Management reported no remaining Zevra Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Fox Run Management sold 10,884 Zevra Therapeutics shares in Q2 2026, an estimated $95.6K.
  • Fox Run Management first reported a position in Zevra Therapeutics in Q2 2025 and held it in 4 quarters.
  • Fox Run Management's Zevra Therapeutics position peaked at $295K in Q3 2025.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.